Lilly(US:LLY) 智通财经网·2025-08-13 12:47Group 1 - The CEO of Eli Lilly (LLY.US) and other executives collectively invested nearly $2.9 million in company stock following a significant drop in share price due to disappointing Phase 3 clinical trial results for the oral weight loss drug orforglipron [1] - The company's stock fell approximately 14% last Thursday, marking the largest single-day decline in over 20 years, after mid-term results from the Phase 3 ATTAIN-1 clinical trial disappointed Wall Street [1] - The insider buying created a rare opportunity for executives to purchase shares at a lower price, with the CEO buying about 1,600 shares at an average price of $644.77 per share, totaling over $1 million [1] Group 2 - Other executives, including the Chief Scientific Officer, also increased their holdings, with significant purchases made by board members, resulting in ownership increases of approximately 5% and 2% for some [1] - In contrast, the President of Eli Lilly's U.S. operations sold about 1,300 shares for approximately $783,800, reducing his stake by about 5% [1] - The recent stock movement has drawn attention from Wall Street, with differing opinions on the stock's potential; some view the decline as a buying opportunity, while others see limited upside for similar investors [2]